June 2026 Biotech Catalysts: 11 FDA Dates & Phase 3 Readouts

KEYNOTE-867 Phase 3 readout for subcutaneous pembrolizumab at ASCO 2026

Subcutaneous pembrolizumab (MK-3475A) · Pan-tumor (NSCLC bridging study)

Merck's subcutaneous Keytruda formulation aims to extend the $30B franchise past its 2028 IV patent cliff. Non-inferior pharmacokinetics and clinical activity versus IV Keytruda would secure patent protection through 2039 and reshape the immuno-oncology defense narrative.

Primary endpoint is PK non-inferiority (Cavgss/Ctrough). Clinical endpoints are exploratory but tracked. Success protects $20B+ of post-2028 Keytruda revenue and removes a major MRK overhang. A miss compresses the multiple substantially.

PDUFA decision for odronextamab in 3L+ DLBCL

Ordspono (odronextamab) · Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

FDA decision on Regeneron's CD20xCD3 bispecific in DLBCL after the 2024 CRL on manufacturing. Approval reopens a $1B+ commercial opportunity and validates Regeneron's bispecific platform versus Roche's Columvi and Genmab's Epkinly.

Approval probability ~75% with CRL issues addressed. Competitive landscape is now crowded; commercial uptake will hinge on label and pricing. Modest stock impact but franchise validation.

REDEFINE-2 Phase 3 cardiovascular outcomes data for CagriSema at ADA 2026

CagriSema (cagrilintide + semaglutide) · Obesity with cardiovascular risk reduction

Novo's GLP-1 + amylin combination CagriSema delivers its first major cardiovascular outcomes data at ADA 2026. The 2024 REDEFINE-1 weight-loss data disappointed at ~22.7% versus a 25%+ expectation. CV outcomes are now the make-or-break story for CagriSema's launch positioning.

MACE hazard ratio target is below 0.85 to justify a CV outcomes label. Strong CV data resets the obesity narrative around NVO and pressures Lilly's Zepbound. A modest CV signal keeps the franchise on its current trajectory.

PDUFA decision for KB407 in cystic fibrosis (inhaled gene therapy)

KB407 · Cystic fibrosis (CFTR-mutation independent)

Krystal's inhaled HSV-1 vector gene therapy targets the 10% of CF patients ineligible for Trikafta. Approval would be the first non-modulator CF therapy delivered topically to the lungs and a transformative growth catalyst for KRYS beyond Vyjuvek dermatology.

Approval not guaranteed; FDA may want longer follow-up on lung function durability. Approval doubles KRYS's commercial trajectory. CRL likely drops the stock 25-35% but doesn't kill the program.

Phase 3 NEXLEVEL-AD topline data for ABBV-383 in Alzheimer's psychosis

ABBV-383 · Alzheimer's disease psychosis

AbbVie's selective serotonin 5-HT2A inverse agonist tries to succeed where Acadia's Nuplazid failed. Approval would carve out a multi-billion dollar Alzheimer's psychosis indication and give ABBV a clear neuroscience franchise leg.

Primary endpoint is SAPS-H+D reduction at week 12. Acadia's HARMONY trial failed on a similar endpoint. AbbVie's selectivity profile differs; success here would be a paradigm validation. Modest single-day impact on ABBV; significant for the neuroscience pipeline narrative.

Phase 3 topline data for efgartigimod in Sjogren's syndrome

Vyvgart (efgartigimod) · Sjogren's syndrome

Argenx pushes its FcRn antagonist Vyvgart into a high-prevalence autoimmune indication with no approved therapies. Approval expands the franchise from neurology (myasthenia gravis, CIDP) into rheumatology and meaningfully extends the peak sales ceiling.

Primary endpoint is ESSDAI score reduction. Phase 2 data was directionally positive. Success expands Vyvgart's TAM by 2-3x. A miss caps the franchise at its current neurology trajectory.

PDUFA decision for lenacapavir for HIV prevention (PrEP)

Sunlenca (lenacapavir) · HIV pre-exposure prophylaxis (PrEP)

FDA decides on Gilead's twice-yearly injectable PrEP. PURPOSE-1 and PURPOSE-2 showed essentially 100% protection against HIV — the best-in-class PrEP data ever generated. Approval anchors a multi-billion dollar HIV prevention franchise and supports GILD beyond the Biktarvy plateau.

Approval near-certain. Commercial uptake is the bigger question given access and pricing dynamics. Approval likely modest single-day impact on GILD but transformative for the long-term HIV franchise.

PATHFNDR-2 Phase 3 topline data for paltusotine in carcinoid syndrome

Paltusotine · Carcinoid syndrome

Crinetics' oral somatostatin analog faces its second pivotal readout in carcinoid syndrome. Following the acromegaly approval expected late 2026, a clean carcinoid readout would establish paltusotine as a once-daily oral replacement for monthly Sandostatin LAR or Somatuline injections.

Primary endpoint is reduction in flushing and diarrhea episodes versus placebo. Phase 2 data was supportive. Success roughly doubles paltusotine's peak sales estimate from ~$1B to ~$2B+.

Phase 2 RP-A501 update in Danon disease at conference

RP-A501 · Danon disease (X-linked cardiomyopathy)

Updated Phase 2 data for Rocket's AAV9 gene therapy for Danon disease — a rare, fatal cardiomyopathy. Sustained improvement in cardiac function and biomarkers would support an accelerated approval pathway.

Watch LAMP2 protein expression, cardiac MRI, NT-proBNP trajectory, and any cardiac event reductions. Clean updated data supports accelerated filing in 2H 2026.

PDUFA decision for TransCon hGH label expansion in adult GHD

Skytrofa (lonapegsomatropin) · Adult growth hormone deficiency

Ascendis seeks adult GHD approval for its weekly growth hormone Skytrofa. Approval triples the addressable market beyond pediatric GHD and adds defensive franchise breadth as competition intensifies.

Approval highly likely given supportive Phase 3. Stock impact modest single-day; meaningful for full franchise trajectory.

Phase 3 Galatea topline data for lotilaner in rosacea

TP-04 (lotilaner ophthalmic) · Demodex-associated facial rosacea

Tarsus extends its Demodex franchise from eyelids (Xdemvy) to facial rosacea. Approval would meaningfully expand the company's commercial reach and de-risk the post-Xdemvy growth story.

Primary endpoint is IGA score reduction. Mechanism is well-validated; success probability is reasonable. Strong data positions TARS for follow-on franchise growth.